Serina Therapeutics, Inc. Common Stock
Key Metrics
Market Snapshot
About
Serina Therapeutics, Inc. Common Stock (SER) is a biotechnology company headquartered in Huntsville, Alabama that develops drugs aimed at neurological diseases and pain. Founded in 2006, it is best known for its work on POZ based drug conjugates and delivery technology intended to improve how certain treatments are administered.
The company's lead product candidate is SER 252, also referred to as POZ-apomorphine, a POZ conjugate being developed for advanced Parkinson's disease. According to the available information, this candidate is in a phase 1 clinical trial. Serina is also developing POZ-lipids, which it describes as a non-immunogenic alternative to the PEG-lipids used in lipid nanoparticles, pointing to a focus on the materials used to carry drugs in the body.
In addition to its lead program, the company is advancing other candidates and platform applications. It is developing SER 214, a POZ conjugate of rotigotine intended for early Parkinson's disease and Restless Leg Syndrome, which the information indicates has completed a phase 1a clinical trial. Serina is also applying its POZ technology to lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases, extending its approach beyond neurology and pain into vaccine delivery. Because its programs are at clinical and developmental stages, the business is centered on research and trials rather than marketed products. Through its POZ conjugates and delivery platform, Serina Therapeutics, Inc. (SER) works to create new options for treating neurological conditions, pain, and infectious disease.